Therapeutic innovations in endocrine diseases – Part 1: New medical treatments for chronic excess of endogenous cortisol (Cushing's syndrome) - 28/05/16
Doi : 10.1016/j.lpm.2016.05.006
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Saturday 28 May 2016
This article has been published in an issue click here to access
This article has been published in an issue click here to access
Summary |
Diverse hormonal, antisecretory, antitumoural or immunomodulatory therapeutic innovations act for broadening the management scope of adrenal, pituitary and endocrine tumours.
In this issue
Innovations in autoimmune diseases
L. Guillevin, France
Stem cell transplantation and mesenchymal cells to treat autoimmune diseases
A. Tyndall, Switzerland, and J.M. van Laar, Netherlands
New therapeutic approaches for ANCA-associated vasculitides
B. Chaigne, L. Guillevin, France
New therapeutic approaches in rheumatoid arthritis
R.F. van Vollenhoven, Sweden
Future treatments for Sjögren's syndrome
J.-O. Pers, A. Saraux, France
Therapeutic innovations in endocrine diseases: part 1: new medical treatments for chronic excess of endogenous cortisol (Cushing's syndrome)
X. Bertagna, France
Therapeutic innovations in endocrine diseases: part 2: modified-release glucocorticoid compounds: what good do they provide to the adrenal insufficient patient?
Y. Reznik, France
Therapeutic innovations in endocrine diseases: part 3: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas
H. Lasolle, G. Raverot, France
Therapeutic innovations in endocrine diseases: part 4: pasireotide: long-acting release somatostatin analogue
J.-L. Wémeau, France
Therapeutic innovations in endocrine diseases: part 5: rituximab and graves’ orbitopathy
M. Ladsous, France
Esquema
© 2016
Elsevier Masson SAS. Reservados todos los derechos.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.